The Effect of Combination of Dapagliflozin and Sildenafil in Treatment of Heart Failure Patients With Secondary Pulmonary Hypertension

Sponsor
Fayoum University
Study ID
NCT06778330
Status
Completed

Conditions

  • Heart Failure NYHA Class II

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin (DAPA) — DRUG
    Control group: receive dapagliflozin in addition to standard therapy
  • Sildenafil — DRUG
    Test group: receive combination therapy of dapagliflozin and a small dose of sildenafil(25mg/day) in addition to standard therapy

Study Details

This study aims to determine the efficacy of sildenafil (improve PAH) as an add-on therapy to dapagliflozin in the treatment of heart failure patients with secondary pulmonary arterial hypertension and compare the result with monotherapy dapagliflozin

Key Dates

Start date
Jan 20, 2025
Status verified
Sep 2025
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025

Study Design

Enrollment
100 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: test group
  • Active Comparator: control group

Primary Outcome Measure

change in ejection fraction [ Time Frame: 12 weeks after treatment ]

Related Studies